Industry News

Aug 16, 2018
By BioPharm International Editors
FDA grants support US research in continuous manufacturing monitoring and control techniques for bio/pharmaceutical manufacturing at Rutgers, MIT, and Georgia Tech.
Aug 15, 2018
By BioPharm International Editors
FDA published a resource guide to promote responsible opioid prescribing in the treatment of animals.
Aug 10, 2018
By BioPharm International Editors
Only 54% of North Americans feel informed about the requirements of the general data protection regulation (GDPR), according to a report by GlobalData.
Aug 10, 2018
By BioPharm International Editors
The agency issued a warning letter to Canadian API manufacturer, Les Produits Chimiques B.G.R, citing cGMP violations at its API facility in Pointe-Claire, Quebec.
Aug 09, 2018
By BioPharm International Editors
The European Medicines Agency (EMA) will temporarily scale back activities as it copes with “significant staff loss” and prepares for the next phase in its continuity plan.
Aug 09, 2018
By BioPharm International Editors
Ebola vaccinations by the World Health Organization began in North Kivu, Democratic Republic of the Congo, one week after the country’s latest outbreak.
Aug 09, 2018
By BioPharm International Editors
The Alliance for Regenerative Medicine’s (ARM) report highlights major trends and metrics from the 2018 second quarter in the regenerative medicines sector.
Aug 08, 2018
By BioPharm International Editors
Avalon and Weill will co-develop bio-production and standardization procedures for CAR-T therapy.
Aug 06, 2018
By BioPharm International Editors
Boehringer Ingelheim joins Oxford BioMedica, UK Cystic Fibrosis Gene Therapy Consortium, and Imperial Innovations to form a partnership for developing a new gene therapy to treat cystic fibrosis.
Aug 03, 2018
By BioPharm International Editors
Researchers at the University of Pennsylvania found that diabetes drugs called thiazolidinediones can promote the metabolism of glutamine to help control disease-causing inflammation.
native1_300x100
lorem ipsum